Form D · Hedge Fund

Avoro Life Sciences Fund LLC

New York, NY · CIK 0001498991

Offering snapshot reported May 1, 2026 · SEC filing

Reported sold: $3.45B
Investors reported: 292
Minimum accepted: $1M
First sale: Jul 1, 2010

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$3,333,063,805 → $3,454,353,055
Reported investors291 → 292

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
May 1, 2026	Amendment	$3,454,353,055	$121,289,250vs May 2, 2025	292	SEC filing
May 2, 2025	Amendment	$3,333,063,805	$167,512,786vs May 2, 2024	291	SEC filing
May 2, 2024	Amendment	$3,165,551,019	$328,907,765vs May 2, 2023	283	SEC filing
May 2, 2023	Amendment	$2,836,643,254	$369,598,237vs May 2, 2022	265	SEC filing
May 2, 2022	Amendment	$2,467,045,017	$502,037,000vs May 3, 2021	251	SEC filing
May 3, 2021	Amendment	$1,965,008,017	$309,426,250vs May 6, 2020	224	SEC filing
May 6, 2020	Amendment	$1,655,581,767	$385,297,500vs May 22, 2019	192	SEC filing
May 22, 2019	Amendment	$1,270,284,267	$69,950,025vs Sep 7, 2018	169	SEC filing
Sep 7, 2018	Amendment	$1,200,334,242	$570,442,500vs Oct 11, 2017	159	SEC filing
Oct 11, 2017	Amendment	$629,891,742	$216,975,000vs Oct 11, 2016	129	SEC filing
Oct 11, 2016	Amendment	$412,916,742	$120,334,213vs Oct 9, 2015	108	SEC filing
Oct 9, 2015	Amendment	$292,582,529	$168,608,029vs Oct 17, 2014	96	SEC filing
Oct 17, 2014	Amendment	$123,974,500	$86,340,000vs Oct 21, 2013	42	SEC filing
Oct 21, 2013	Amendment	$37,634,500	$15,799,500vs Oct 18, 2012	12	SEC filing
Oct 18, 2012	Amendment	$21,835,000	$6,325,000vs Aug 1, 2011	9	SEC filing
Aug 1, 2011	Amendment	$15,510,000	$14,500,000vs Aug 13, 2010	4	SEC filing
Aug 13, 2010	Initial	$1,010,000	No comparison	2	SEC filing

Offering details

Securities: Pooled investment fund
Exemptions: 06b, 3C, 3C.7
Duration over one year: Yes
Business combination: No

Sales commissions: $37.2M (estimated)
Finders' fees: $0 (estimated)
Form D file number: 021-146405

The issuer is a master fund, the amount sold includes subscriptions into its feeder fund.

Sales compensation recipients

Scroll to see all columns →

Recipient	CRD	Associated broker-dealer
Far Hills Group LLC	000032243

Source: Form D, filed May 1, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

The linked fund shows its most recently reported ADV details.

Matched by reported Form D file number

AVORO LIFE SCIENCES FUND LLC

Investment adviser: AVORO CAPITAL ADVISORS LLC

Gross asset value: $13.4B
Beneficial owners: 415
ADV minimum commitment: $1M

Reported in Form ADV on Mar 5, 2026. Fund assets and beneficial owners measure different things from Form D sales and investors.

Service providers

Fund administrator HEDGESERV (CAYMAN), LTD. C/O HEDGESERV CORPORATION NEW YORK, New York, United States Investor statements: Yes (provided to all investors) Related to adviser: No

Auditor KPMG SAN FRANCISCO, California, United States

Custodian GOLDMAN SACHS & CO. LLC NEW YORK, New York, United States Related to adviser: No

Custodian J.P. MORGAN SECURITIES LLC NEW YORK, New York, United States Related to adviser: No

Custodian MORGAN STANLEY & CO. LLC NEW YORK, New York, United States Related to adviser: No

Prime broker GOLDMAN SACHS & CO. LLC NEW YORK, New York, United States

Prime broker J.P. MORGAN SECURITIES LLC NEW YORK, New York, United States

Prime broker MORGAN STANLEY & CO. LLC NEW YORK, New York, United States

Provider details

Annual audit: Yes
Prime brokers: Yes
Custodians: Yes
Administrator other than the adviser: Yes
External marketing: No

KPMG
PCAOB 185

GOLDMAN SACHS & CO. LLC
SEC 8-129

J.P. MORGAN SECURITIES LLC
SEC 8-35008

MORGAN STANLEY & CO. LLC
SEC 8-15869

GOLDMAN SACHS & CO. LLC
CRD 361 · SEC 8-129

J.P. MORGAN SECURITIES LLC
CRD 79 · SEC 8-35008

MORGAN STANLEY & CO. LLC
CRD 8209 · SEC 8-15869

Filing source

Form ADV 2061300 · Mar 5, 2026 · Schedule D 7.B.(1), fund 805-5609721763

Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Robert Adelman	Executive
Behzad Aghazadeh	Executive
Avoro Capital Advisors Llc	Promoter
Avoro Capital Gp, Llc	Promoter
Avoro Capital L.P.	Promoter
Paul Brooke	Executive
Neil Cammarosano	Executive
Scott Epstein	Executive
Corey Goodman	Executive
Llc Ven Bio Select Advisor	Promoter
N/A Ven Bio Select Advisor Llc	Promoter
N/A Ven Bio Select Advisor L.P.	Promoter
N/A Ven Bio Select Advisor Management Holdings Gp, Llc	Promoter
Kurt Von Emster	Executive

Issuer details

Industry: Pooled Investment Fund (See others in industry)

Address:

110 Greene Street Suite 800
New York, NY, 10012